CRSP News and Press, CRISPR Therapeutics AG From 03/16/24

2024-03-16 08:45:00 ET CRISPR Therapeutics (NASDAQ: CRSP) is gaining in prominence. The gene-editing specialist has made tremendous clinical and regulatory progress since its 2016 initial public offering, leading to market-beating returns even if it hasn't always been smooth sailing...

2024-03-13 14:25:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks . T...

2024-03-08 13:47:20 ET More on CRISPR Therapeutics Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade) Crispr Therapeutics: Cautiously Optimistic CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conferen...

2024-03-05 18:53:38 ET CRISPR Therapeutics (NASDAQ: CRSP) was a standout in the market last month as its shares charged 34% higher, according to data provided by S&P Global Market Intelligence . The biotech stock sustained its momentum from prior months with a strong qua...

2024-03-01 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-29 06:31:00 ET Just one day after the ascendant biotech CRISPR Therapeutics (NASDAQ: CRSP) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the stock to $112, suggesting that it could rise by 32% from its cu...

2024-02-26 08:50:00 ET The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem likely to happen in the next de...

2024-02-26 06:45:00 ET The hunt for winning biotech stocks never truly ends, and it's easy to see why. Over the last five years, shares of the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) are up by 146%, easily topping the market's return of 94%. The company recently succ...

2024-02-24 08:30:00 ET Summary CRISPR stock fell nearly 30% in December but has since rebounded, gaining almost 65% through its recent highs. The recent FDA approvals of Crispr's gene-editing therapy have increased the actualization of its growth potential, improving investor sent...

2024-02-21 18:04:03 ET CRISPR Therapeutics AG (CRSP) Citi 2024 Virtual Oncology Leadership Summit Conference February 21, 2024, 01:00 PM ET Company Participants Samarth Kulkarni - Chairman and Chief Executive Officer Conference Call Participants Yigal Nochomo...